Acusphere to Present at the 8th US-Japan Symposium on Drug Delivery Systems.WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ACUS acus (a´kus) a needle or needle-like process. acus a needle or needle-like process. ) today announced today that Dr. Allan Miller, a director of Acusphere's Drug Delivery Business Unit, is scheduled to make a presentation on the "Application of Porous Microparticle Technology for the Intravenous Delivery of Gas" at the 8th US-Japan Symposium on Drug Delivery Systems. Dr. Miller's presentation will focus on porous microparticle technology and its advantages and application as an ultrasound contrast agent. The presentation will take place on Thursday, December 22, 2005 at The Westin Maui, Lahaina, Maui, Hawaii at 8:00AM Hawaiian Standard Time. The Symposium offers presentations by researchers from a number of disciplines, from the life sciences to engineering, who will address a range of topics including peptide and protein delivery, gene delivery, cell delivery, vaccines, transdermals, pulmonary delivery, new materials, and other subjects, all focused on the central theme of drug delivery. The Symposium offers an opportunity for interaction and networking among attendees from academia and industry. The Symposium's US Chairman is Dr. Robert Langer, the Kenneth Germeshausen Professor of Chemical and Biomedical Engineering Biomedical engineering An interdisciplinary field in which the principles, laws, and techniques of engineering, physics, chemistry, and other physical sciences are applied to facilitate progress in medicine, biology, and other life sciences. at the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, and a co-founder of Acusphere. Acusphere is also a sponsor of the Symposium. About Acusphere, Inc. Acusphere (NASDAQ: ACUS) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's three initial product candidates are designed to address large unmet clinical needs within cardiology, oncology and asthma. These product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, AI-700, is a cardiovascular drug in Phase 3 clinical development. AI-700 is designed to enable ultrasound to compete more effectively with nuclear stress testing Determining the durability of a system by pushing it to its limits. Stress testing a network is performed by transmitting excessive numbers of packets or attempting to break in illegally. , the leading procedure for detecting coronary heart disease coronary heart disease: see coronary artery disease. coronary heart disease or ischemic heart disease Progressive reduction of blood supply to the heart muscle due to narrowing or blocking of a coronary artery (see atherosclerosis). . An estimated 10.7 million procedures are done each year in the U.S. to detect coronary heart disease, the leading cause of death in the United States. For more information about Acusphere visit the Company's web site at www.acusphere.com. "Acusphere" is a trademark of Acusphere, Inc. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: Comments made within the aforementioned presentation regarding Acusphere, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward- looking statements, see "Risk Factors" in the Company's most recent Form 10-Q Form 10-Q See 10-Q. for the fiscal period ending on September 30, 2005. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion